Table 4.

Impact of Women's Health Initiative on Hormone Therapy Prescribing by Practice Site, Reported as Percentages

	HVMAa				GHa
	Use more	No change	Use less	Don't use	Use more	No change	Use less	Don't use
Estrogens
Oral unopposed estrogen in women who have had a hysterectomy	0.8	31.3	66.4	1.6	0.5	33.9	63.8	1.8
Combination oral estrogen plus progestin in women with a uterus	0.8	13.3	84.4	1.6	0.9	16.4	80.6	2.1
Low-dose estrogen products	48.0	18.9	31.5	1.6	52.6	20.1	25.2	2.1
Vaginal estrogen***	56.3	29.7	12.5	1.6	41.6	43.2	10.2	5.1
Transdermal estrogen products***	22.8	26.8	30.7	19.7	15.1	40.7	23.4	20.8
Estring***	61.4	13.4	8.7	16.5	25.2	24.0	7.4	43.4
Oral testosterone with estrogen***	2.3	27.3	15.6	54.7	4.2	40.6	20.9	34.3
Bioidentical estrogen or progestogen	8.6	23.4	16.4	51.6	12.5	31.2	13.9	42.5
Ultra low-dose estrogen patch***	11.8	12.6	3.9	71.7	3.7	12.7	4.2	79.5
Progestogens
Medroxyprogesterone acetate***	0.8	36.2	32.3	30.7	1.4	52.3	35.7	10.7
Other oral progestogen***	7.1	31.0	16.7	45.2	6.3	45.9	26.2	21.6
Sequential progestogen (e.g., 10–14 days per month)**	3.2	27.2	31.2	38.4	2.1	39.1	32.9	25.9
Continuous progestogen (e.g., daily)**	1.6	31.8	27.8	38.9	3.0	42.7	28.3	26.0
Long-cycle progestogen (e.g., 2 weeks to two times a year)***	10.2	17.3	13.4	59.1	2.8	21.1	16.0	60.2
Transdermal progestogen	3.2	17.5	4.0	75.4	3.2	21.3	10.4	65.1
Other
Testosterone cream for decreased libido**	6.3	29.1	3.9	60.6	8.8	41.6	5.1	44.6

^aThe number of HVMA respondents ranged from 125 to128; GH from 431 to 434.

^**Statistically significant difference between GH and HVMA, p < 0.05.

^***Statistically significant difference between GH and HVMA, p ≤ 0.01